Linklaters with Bayer on Apollo´s €3bn investment in LARC business
Linklaters has advised Bayer on Apollo´s €3bn equity capital investment in its long acting reversible contraceptives business. Under the agreement, Apollo-managed funds and affiliates will obtain a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer will retain a majority stake in the entity and will continue to exercise complete operational control over the business.
The transaction is expected to close in the third quarter of 2026, subject to approval by antitrust authorities and customary closing conditions.
The Linklaters team
The Linklaters team working on the matter was led by partners Carl Sanders (private capital) and Alexander Schlee (capital markets) and counsel Nikita Selivanov (private capital). The lineup further included partners Arne Kießling (Dusseldorf), Guido Portier, Marleen Wessel (both Amsterdam), Oliver Rosenberg (tax), counsels Anna-Livia von Lüdinghausen and Isabelle-Carmen Petersen Weis (banking), managing associates Philipp Meyer Reichen, Tobias Buddemeier (corporate/M&A), and Sebastian Plötz, associates Lena Mühleisen (private capital), Ruth van der Haar, Carolien Lode (both Amsterdam, corporate/M&A), Pascal Janssen Jägers (tax).
